IXICO plc announced that it has signed a contract with a new US headquartered client to provide imaging services for a Phase 2 Huntington's Disease clinical trial. The contract value, to be delivered over approximately 2.5 years, is worth over PS0.5 million to IXICO. Huntington's Disease is a rare, hereditary neurodegenerative disorder that leads to the progressive breakdown of nerve cells in the brain, affecting motor skills, cognitive function, mood, and emotional well-being.
The contract award reinforces IXICO's sustained positive commercial momentum, as highlighted in the Company's FY24 Final Results, and aligns with its strategic pillars of 'Innovate, Lead, Scale' to drive expansion and growth. Throughout 2024, IXICO has also secured additional clinical trial contracts across key therapeutic areas, including Huntington's Disease, Parkinsonian Disorders, and Alzheimer's Disease.